Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Tumor-derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas

  • Segura-Collar, Berta
  • Garranzo-Asensio, Maria
  • Herranz, Beatriz
  • Hernandez-SanMiguel, Esther
  • Cejalvo, Teresa
  • Casas, Bárbara S
  • Matheu, Ander
  • Pérez-Núñez, Ángel
  • Sepúlveda-Sánchez, Juan Manuel
  • Hernández-Laín, Aurelio
  • Palma, Verónica
  • Gargini, Ricardo
  • Sánchez-Gómez, Pilar
The extraordinary plasticity of glioma cells allows them to contribute to different cellular compartments in tumor vessels, reinforcing the vascular architecture. It was recently revealed that targeting glioma-derived pericytes, which represent a big percentage of the mural cell population in aggressive tumors, increases the permeability of the vessels and improves the efficiency of chemotherapy. However, the molecular determinants of this transdifferentiation process have not been elucidated. Here we show that mutations in epidermal growth factor receptor (EGFR) stimulate the capacity of glioma cells to function as pericytes in a BMX (bone marrow and X-linked) and SOX9-dependent manner. Subsequent activation of platelet-derived growth factor receptor beta (PDGFRβ) in the vessel walls of EGFR mutant gliomas stabilized the vasculature and facilitated the recruitment of immune cells. These changes in the tumor microenvironment conferred a growth advantage to the tumors but also rendered them sensitive to pericyte-targeting molecules such as ibrutinib or sunitinib. In the absence of EGFR mutations, high-grade gliomas were enriched in blood vessels but showed a highly disrupted blood-brain-barrier due to the decreased BMX/SOX9 activation and pericyte coverage, which led to poor oxygenation, necrosis, and hypoxia. Overall, these findingds identify EGFR mutations as key regulators of the glioma-to-pericyte transdifferentiation, highlighting the intricate relationship between the tumor cells and their vascular and immune milieu. Our results lay the foundations for a vascular-dependent stratification of gliomas and suggest different therapeutic vulnerabilities determined by the genetic status of EGFR.
Repisalud
Publication Artículo científico (JournalArticle)

High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

  • Arrizabalaga, Olatz
  • Moreno-Cugnon, Leire
  • Auzmendi-Iriarte, Jaione
  • Aldaz, Paula
  • Ibanez de Caceres, Inmaculada
  • Garros-Regulez, Laura
  • Moncho-Amor, Veronica
  • Torres-Bayona, Sergio
  • Pernía, Olga
  • Pintado-Berninches, Laura
  • Carrasco-Ramirez, Patricia
  • Cortes-Sempere, María
  • Rosas, Rocío
  • Sánchez-Gómez, Pilar
  • Ruiz, Irune
  • Caren, Helena
  • Pollard, Steven
  • Garcia, Idoia
  • Sacido, Angel-Ayuso
  • Lovell-Badge, Robin
  • Belda-Iniesta, Cristobal
  • Sampron, Nicolas
  • Perona, Rosario
  • Matheu, Ander
The elucidation of mechanisms involved in resistance to therapies is essential to improve the survival of patients with malignant gliomas. A major feature possessed by glioma cells that may aid their ability to survive therapy and reconstitute tumors is the capacity for self-renewal. We show here that glioma stem cells (GSCs) express low levels of MKP1, a dual-specificity phosphatase, which acts as a negative inhibitor of JNK, ERK1/2, and p38 MAPK, while induction of high levels of MKP1 expression are associated with differentiation of GSC. Notably, we find that high levels of MKP1 correlate with a subset of glioblastoma patients with better prognosis and overall increased survival. Gain of expression studies demonstrated that elevated MKP1 impairs self-renewal and induces differentiation of GSCs while reducing tumorigenesis in vivo. Moreover, we identified that MKP1 is epigenetically regulated and that it mediates the anti-tumor activity of histone deacetylase inhibitors (HDACIs) alone or in combination with temozolomide. In summary, this study identifies MKP1 as a key modulator of the interplay between GSC self-renewal and differentiation and provides evidence that the activation of MKP1, through epigenetic regulation, might be a novel therapeutic strategy to overcome therapy resistance in glioblastoma.